Celcuity Inc. (NASDAQ:CELC) Targets Hormone-Positive Breast Cancer with Promising Drug Gedatolisib

• Celcuity Inc. (NASDAQ:CELC) has made significant progress with its drug gedatolisib, showing strong phase 3 data and driving investor confidence.

• Needham set a price target of $95 for CELC, indicating a potential increase of approximately 31.69% from its current price.

• The company's market valuation has surged to $2 billion, with a stock price increase of 40.05%, highlighting strong market interest and potential for growth.

Celcuity Inc. (NASDAQ:CELC) is a biotechnology company focused on developing innovative therapies for cancer treatment. The company is currently making headlines due to its promising drug, gedatolisib, which targets hormone-positive breast cancer. Celcuity's competitors include other biotech firms working on cancer therapies, but its recent advancements have set it apart in the market.

On October 20, 2025, Needham set a price target of $95 for CELC, suggesting a potential price increase of approximately 31.69% from its then-current price of $72.14. This optimistic outlook aligns with Celcuity's recent achievements, including the release of strong phase 3 data for gedatolisib. The drug's success in the VIKTORIA-1 trial, which demonstrated substantial benefits in progression-free survival, has been a key driver of investor confidence.

Celcuity's market valuation has surged to $2 billion, reflecting the market's positive response to gedatolisib's potential. The stock price has also seen a significant increase, currently priced at $72.77, marking a 40.05% rise with a change of $20.81. The stock has fluctuated between $71.57 and $83 today, with a 52-week high of $83 and a low of $7.58, indicating strong investor interest and market volatility.

The company's financial position is robust, supported by recent fundraising efforts and loan facilities. This financial stability ensures a cash runway extending into 2027, which is crucial for Celcuity's plans to file a New Drug Application (NDA) for gedatolisib. The potential approval and initial launch of the drug could further enhance Celcuity's market position and financial performance.

With a market capitalization of approximately $3.09 billion and a trading volume of 5,875,995 shares, Celcuity is well-positioned in the biotech sector. The company's focus on hormone-positive breast cancer and its strategic financial planning underscore its potential for growth and success in the competitive biotech landscape.